
ABOUT CITELINE
Citeline powers a full suite of complementary business intelligence offerings to meet the evolving needs of health care professionals to accelerate the connection of treatments to patients and patients to treatments. These patient-focused solutions and services deliver and analyze data used to drive clinical, commercial and regulatory-related decisions and create real-world opportunities for growth.
Our global teams of analysts, journalists and consultants keep their fingers on the pulse of the pharmaceutical, biomedical and medtech industries, covering it all with expert insights: key diseases, clinical trials, drug R&D and approvals, market forecasts and more.
FEATURED CONTENT
-
Get insight from the 2023 first quarter gene, cell, and RNA therapies report composed by Citeline, in conjunction with the American Society of Gene & Cell Therapy (ASGCT).
-
Get a glimpse of how the pharmaceutical industry has emerged from the tumultuous episode of the COVID-19 pandemic, stronger and emboldened.
-
In a sequel to the Pharma R&D Report, the author explores drugs that brought something genuinely new to the world of medicine in 2022 — new active substances (NASs) with some kind of novelty — that just might change the story of patients’ lives.
-
Many observers believe deal volume will remain buoyant throughout 2023. The need for access to cash is expected to continue to drive M&A decision-making. Heightened regulatory scrutiny, supply chain weakness, and consolidation are a few of the trends to watch for the remainder of the year.
-
See what industry organizations are saying about trial transparency, regulations by region, what penalties are on the books, and whether they are enforced.
-
Although COVID-19 has not quite finished its final act, it appears the industry is emerging from this tumultuous episode stronger and emboldened. Find out if the 2023 pipeline was a page-turner in this literary-themed Pharmaprojects’ 2023 review of trends in pharmaceutical R&D.
-
The CEO of one of the global top five CROs recently pointed out an opportunity in decentralized trials that might be a “game changer” in the pharma industry over the next five years. He also refers to the need to accept new technologies by both clinical trial sites and regulators.
-
Co-Founder of Farapulse and Field Medical Steven Mickelsen and Medtech Insight Editor Reed Miller discuss pulsed field ablation, an emerging technology that is changing electrophysiology.
-
Explore the current DCT landscape and its evolution, as well as the key advantages of incorporating decentralized attributes and how barriers to their inclusion can be overcome.
-
Hear from Steven Mickelsen, a pioneer in pulsed field ablation (PFA), as he delves into how PFA is set to change the electrophysiology market as well as his experiences as a physician-entrepreneur.
-
Learn how review divisions may take a tougher line with sponsors on the design and timing of studies to verify clinical benefit.
-
In part two of a survivor series, several individuals who beat breast cancer, and their loved ones, discuss the challenges and treatments they underwent while fighting the disease.
-
As told by survivors of breast cancer and their loved ones, learn about the treatments, and challenges they all faced while battling the disease.
-
Get insight from the 2022 fourth quarter gene, cell, and RNA therapies report composed by Citeline, in conjunction with the American Society of Gene & Cell Therapy (ASGCT).
-
Read about why CROs must fully understand how the nuances of regulatory compliance, particularly clinical trial disclosure, fit into and impact the entire lifespan of a study.
-
Gain insight from leaders representing unique facets of the clinical trial ecosystem. See what they have to say about stakeholder relationships, diversity in clinical trials, smoothing the path to treatment options, the importance of transparency, and more.
-
A large pharmaceutical company was looking to validate its list of 100+ US sites for a chronic auto-immune disease study. Leveraging medical claims data, a site-level analysis was conducted to identify relevant patients meeting the trial’s I/E criteria.
-
Regulatory intelligence goes beyond ensuring compliance. By monitoring and understanding these integral disclosure obligations, sponsors can position clinical trials for seamless completion from the start, and position themselves as industry leaders.
-
New government disclosure regulations are emerging. Regulations from public health organizations around the globe have increased administrative compliance tasks and driven up the consequences of noncompliance.
-
Discover the current state of innovation in Europe, from pipeline constitution to emerging drug modalities, R&D alliances to financing trends.
CONTACT INFORMATION
Citeline
605 Third Ave.
New York, NY 10158
UNITED STATES
Phone: 1 212-600-3530
Contact: Steven Horlock
FEATURED SOLUTIONS
- Revolutionizing Engagement, Education, & Enrollment Across Clinical Portfolios
- Citeline’s Pharmaprojects & Biomedtracker Solution
- TrialScope Intelligence Disclosure Regulatory Tracking
- Widen The Trial Recruitment Funnel, Streamline Engagement, & Enrollment
- Pharmaprojects By Citeline
- Real World Data Solutions
- Helping Sponsors Keep Up With The Latest Clinical Trials Intelligence
- Comprehensive Data And Analytics For Cell, Gene, And RNA-Based Therapies
- TrialScope Disclosure Services Workshops
- RWD Solutions
- Citeline Connect: The All-In-One Clinical Trial Recruitment Platform
- TrialScope Disclose
- Cell And Gene Therapy Insights
- Citeline Engage Trial Transparency Website
- Integrate Your Data To Get The Full Picture
FEATURED WEBINARS
-
Listen in as industry leaders discuss how to meet the needs of multiple stakeholders while ensuring operational efficiency, study success, and enterprise scale.
-
See the results of a joint survey with 1nHealth on how compensation is likely to impact participation in clinical trials, followed by a thought-provoking roundtable on this timely topic.
-
In this webinar, discover the trends shaping pharma’s R&D pipeline, with data broken down by therapeutic area, disease, mechanism and target, and drug type.
-
Now that the EU’s Clinical Trials Information System (CTIS) is up and running, disclosure and transparency experts from Sarepta, Boehringer Ingelheim, Bayer and Merck KgaA discuss the ins and outs of registering clinical trials and submitting study information to the portal.
-
Disclosure experts Thomas Wicks and Francine Lane explain the importance of consistency and creating a disclosure template, plain language summaries source documents, and authoring with redaction in mind.
-
In this informative webinar, clinical trial disclosure experts Francine Lane and Thomas Wicks provide a high-level overview of EU CTR/CTIS regulations, show how they differ from the EU CTD directive, share timelines for compliance, and discuss the scope of data sharing.
-
In this presentation delivered at SCOPE 2022, hear how ICON leveraged Study Feasibility to its advantage.
-
Because there are no regulations mandating study diversity, it is up to sponsors to take the lead. In this webinar, panelists discuss how trust, accessibility and technology combine to improve the diversity of clinical trial of participants.
-
When Craig Lipset talks pharma, people listen. The former Head of Clinical Innovation and Venture Partner at Pfizer shares his insights on clinical trial transparency and is joined by Chris Boone of AbbVie in a fireside chat.
-
In this panel discussion, Teva and Lung Biotechnology disclosure experts discuss why they opted for disclosure as a service. They will detail how it helps them safeguard regulatory compliance and mitigate risk.